Skip to main content

Table 2 Results of system suitability parameters of 100% level standard solution

From: An effective stability indicating RP-HPLC method for simultaneous estimation of Dolutegravir and Lamivudine in bulk and their tablet dosage form

InjectionDolutegravirLamivudine
RTPeak areaUSP plate count (N)USP tailing (T)RTPeak areaUSP plate count (N)USP tailing (T)
15.0654,131,30799231.053.34710,699,76971441.05
25.0684,144,85199431.063.34910,691,54071721.06
35.0684,155,26310,0221.063.34810,713,74671201.06
45.074,185,44710,0931.063.34910,794,46970331.06
55.074,180,12210,0791.063.34810,783,85470371.05
65.074,199,70710,1201.063.34910,844,34470791.06
Mean5.0684,166,11610,0301.0593.34810,754,6207097.51.06
SD0.00226,381.381.920.0040.000861,88957.20.0048
%RSD0.0390.630.810.390.00240.580.800.44
  1. SD standard deviation, %RSD relative standard deviation, RT retention time
  2. Acceptance limit % RSD (≤ 2), USP tailing factor (≤ 2), and USP plate count (> 2000)